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Despite recent advances in blood screening techniques,
transfusions are not risk-free. Therefore, screening for
viral and bacterial infections as well as other, newly-
emerging agents continues to attract attention in the
medical and health policy communities. At the same 
time, governments and other decision-making bodies
increasingly use cost-effectiveness analyses to justify (or
reject) allocation of limited ﬁnancial resources to new
technologies.
OBJECTIVES: To assess the cost-effectiveness of com-
monly employed blood safety interventions, and compare
those cost effectiveness levels with other accepted injury
prevention measures.
METHODS: Using MEDLINE, we conducted a literature
review on the cost-effectiveness of various transfusion-
relevant blood safety interventions. We identiﬁed 16
studies (published between 1993 and 2000) of blood
safety interventions that evaluated their economic beneﬁt
as either a cost per QALY or cost per life year (LY). These
interventions included several testing procedures for
transfusion donations (such as viral screening procedures
for HIV) and medical procedures (such as autologous
blood transfusion in elective surgery and epoietin
therapy). Most technologies related to testing and pro-
cessing blood donations are now standard practice in the
USA and Europe.
RESULTS: A majority of blood safety interventions had
cost-effectiveness ratios greater than $200,000 per QALY
or LY. Fewer than 35% had cost-effectiveness ratios less
than $50,000 per QALY or LY.
CONCLUSIONS: Many blood safety and injury preven-
tion regulations have cost-effectiveness ratios well above
$50,000 per QALY. Although $50,000 per QALY is 
recognized as the standard threshold value against 
which medical technologies are evaluated, many com-
monly accepted blood safety interventions and injury pre-
vention measures have much higher cost effectiveness
ratios. This indicates that society places a high value on
the risks prevented or reduced by such measures and sug-
gests that innovative blood safety technologies should be
assessed against a higher cost-effectiveness threshold.
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OBJECTIVES: The Human Genome Project has the
potential to revolutionize every aspect of pharmaceutical
science and the pharmaceutical industry. Pharmaco-
genomics is a new discipline with the goal of under-
standing the genetic basis for how individuals differ in
their response to drugs. However, there has not been a
systematic review of what is known about the societal
implications of these developments. Our objective is to:
(1) develop a framework for reviewing the clinical, eco-
nomic, and policy implications of pharmacogenomics,
and (2) systematically review the literature to assess what
is currently known about these issues.
METHODS: Our analysis builds on our previous sys-
tematic review of the impact of pharmacogenomics on
adverse drug reactions. We used systematic literature
review and data gathering to develop the framework and
to assess the literature.
RESULTS: We developed a framework that examines 
the implications of using pharmacogenomics from three
views: (1) Perspective (basic science, clinical, or policy
science), (2) Approach (drug development, drug substitu-
tion, or genotyping), and (3) Stakeholders (patients,
providers, industry, payers, government, or society). We
found that there are many existing gaps in the literature
examining these issues. Much of the literature has focused
on the use of genetic information to predict disease 
risk, such as genetic predisposition for breast cancer, but
these studies often do not address the relevant issues for
pharmacogenomics.
CONCLUSIONS: Only a few studies have begun to
address the economic impact of introducing genotyping
as a guide for individual therapy and the implications 
for health care provision and ﬁnancing. It will thus be
critical to conduct cost-effectiveness analyses and other
evaluations of the clinical, economic, and policy impact
of pharmacogenomics.
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OBJECTIVES: There has been substantial interest in 
a Medicare drug beneﬁt program. Little attention has
focused on ensuring improved access to medication mon-
itoring for Medicare beneﬁciaries. Using a societal per-
spective, we evaluated the impact pharmacists could have
on inappropriate prescribing, patient compliance and
medication-related morbidity and mortality within a
Medicare Drug Beneﬁts program.
METHODS: To the extent possible, the cost-effectiveness
modeling followed the methodology guidelines of the US
Public Health Service Task Force on Cost Effectiveness
Analysis. Data sources and model parameters were iden-
tiﬁed by conducting a comprehensive Medline search for
relevant literature.
